Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Saved in:
| Title: | Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. |
|---|---|
| Authors: | Hack SP; Product Development (Oncology), Genentech, Inc., South San Francisco, CA, United States., Zhu AX; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, United States.; Jiahui International Cancer Center, Jiahui Health, Shanghai, China., Wang Y; Product Development (Oncology), Genentech, Inc., South San Francisco, CA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2020 Nov 05; Vol. 11, pp. 598877. Date of Electronic Publication: 2020 Nov 05 (Print Publication: 2020). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33250900 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Product Development (Oncology), Genentech, Inc., South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Zhu+AX%22">Zhu AX</searchLink>; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, United States.; Jiahui International Cancer Center, Jiahui Health, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Product Development (Oncology), Genentech, Inc., South San Francisco, CA, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2020 Nov 05; Vol. 11, pp. 598877. <i>Date of Electronic Publication: </i>2020 Nov 05 (<i>Print Publication: </i>2020). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33250900 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fimmu.2020.598877 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 598877 Titles: – TitleFull: Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hack SP – PersonEntity: Name: NameFull: Zhu AX – PersonEntity: Name: NameFull: Wang Y IsPartOfRelationships: – BibEntity: Dates: – D: 05 M: 11 Text: 2020 Nov 05 Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1664-3224 Numbering: – Type: volume Value: 11 Titles: – TitleFull: Frontiers in immunology Type: main |
| ResultId | 1 |
